Malignant Melanoma – Unmet Need – Detailed, Expanded Analysis: BRAF Mutation-Positive Unresectable or Metastatic Malignant Melanoma

The treatment of BRAF mutation-positive unresectable or metastatic malignant melanoma has been transformed by the development of immune checkpoint inhibitors (e.g., Keytruda, Opdivo, Tecentriq) and BRAF/MEK inhibitors (e.g., Tafinlar, Mekinist, Braftovi, Mektovi). These agents can be used alone or in combination (e.g., Opdivo plus Yervoy, Tecentriq in combination with Zelboraf plus Cotellic), but despite the remarkable survival data demonstrated by combination therapies, patients ultimately experience disease progression. Key challenges that remain include overcoming the relatively low response rates associated with immunotherapies and the relatively short duration of response associated with BRAF/MEK inhibitors and optimizing the sequence of therapies.


  • How satisfied are U.S. and European medical oncologists with the current treatments for BRAF mutation-positive unresectable or metastatic malignant melanoma?
  • What treatment drivers and goals are most likely to influence the choice of therapy in this crowded patient population?
  • How do current therapies, such as immune checkpoint inhibitor and BRAF/MEK combinations, perform on key treatment drivers and goals?
  • What trade-offs across different clinical attributes and prices are acceptable to U.S. and European medical oncologists for a hypothetical new BRAF mutation-positive unresectable or metastatic malignant melanoma treatment?


Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 63 U.S. and 31 European medical oncologists fielded in March 2021

Key companies: Bristol Myers Squibb, Merck & Co., Roche, Novartis, Pfizer, Amgen

Key drugs: Opdivo, Yervoy, Keytruda, Tecentriq, Tafinlar, Mekinist, Braftovi, Mektovi, Zelboraf, Cotellic, Imlygic

Table of contents

launch Related Market Assessment Reports